135 related articles for article (PubMed ID: 38739083)
1. Sixty Years of Hemodynamic Pharmacology in Obstructive Hypertrophic Cardiomyopathy.
Ommen SR
N Engl J Med; 2024 May; 390(20):1914-1915. PubMed ID: 38739083
[No Abstract] [Full Text] [Related]
2. The end of the beginning for drug therapy in obstructive hypertrophic cardiomyopathy with EXPLORER-HCM.
Elliott PM
Cardiovasc Res; 2020 Nov; 116(13):e175-e178. PubMed ID: 33096564
[No Abstract] [Full Text] [Related]
3. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
[TBL] [Abstract][Full Text] [Related]
4. [Echocardiographic and hemodynamic studies on the influence of verapamil in hypertrophic obstructive cardiomyopathy (author's transl)].
Schmid P; Pavek P; Klein W
Z Kardiol; 1979 Feb; 68(2):89-92. PubMed ID: 570768
[TBL] [Abstract][Full Text] [Related]
5. [Drug therapy of hypertrophic cardiomyopathy].
Hartmann A; Kaltenbach M; Hopf R
Fortschr Med; 1992 Sep; 110(27):485-8. PubMed ID: 1358773
[TBL] [Abstract][Full Text] [Related]
6. [Diastolic heart function. Pathophysiology, possibilities for evaluation and modifiability].
Modersohn D; Walde T; Bruch L
Z Arztl Fortbild (Jena); 1993 Feb; 87(2):111-21. PubMed ID: 8094928
[No Abstract] [Full Text] [Related]
7. Mid-ventricular obstructive hypertrophic cardiomyopathy during pregnancy complicated by preeclampsia and acute myocardial infarction: a case report.
Singla A; Lipshultz SE; Fisher S
Congenit Heart Dis; 2011; 6(3):257-61. PubMed ID: 21418527
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic studies of beta blockade in hypertrophic obstructive cardiomyopathy.
Swanton RH; Brooksby IA; Jenkins BS; Webb-Peploe MM
Eur J Cardiol; 1977 Jun; 5(4):327-41. PubMed ID: 196858
[No Abstract] [Full Text] [Related]
9. Invasive Hemodynamics of Myocardial Disease: Systolic and Diastolic Dysfunction (and Hypertrophic Obstructive Cardiomyopathy).
Eskander M; Kern MJ
Interv Cardiol Clin; 2017 Jul; 6(3):297-307. PubMed ID: 28600085
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hypertrophic obstructive cardiomyopathy with verapamil.
Kaltenbach M; Hopf R; Kober G; Bussmann WD; Keller M; Petersen Y
Br Heart J; 1979 Jul; 42(1):35-42. PubMed ID: 573129
[TBL] [Abstract][Full Text] [Related]
11. Adverse effects of nifedipine therapy on hypertrophic obstructive cardiomyopathy.
Fedor JM; Stack RS; Pryor DB; Phillips HR
Chest; 1983 Apr; 83(4):704-6. PubMed ID: 6682029
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and hemodynamic effects of verapamil in hypertrophic obstructive cardiomyopathy].
Lösse B; Kuhn H; Loogen F
Z Kardiol; 1982 Dec; 71(12):813-9. PubMed ID: 6891873
[No Abstract] [Full Text] [Related]
13. [Results of long-term verapamil treatment of patients with hypertrophic cardiomyopathy].
Dabrowski M; Michalak E; Maurin A; Rydlewska-Sadowska W; Ruzyłło W
Kardiol Pol; 1989; 32 Suppl 2():6-16. PubMed ID: 2634154
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular diastolic pulsus alternans in hypertrophic cardiomyopathy.
Yamakado T; Oomichi C; Maeda M; Yamada N; Shibata M; Kakimoto H; Nakano T
Heart Vessels; 1994; 9(5):969-72. PubMed ID: 7814304
[TBL] [Abstract][Full Text] [Related]
15. [Drug treatment of hypertrophic cardiomyopathy].
Hirzel HO
Herz; 1985 Apr; 10(2):84-90. PubMed ID: 4039293
[TBL] [Abstract][Full Text] [Related]
16. Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy.
Betocchi S; Piscione F; Losi M A; Pace L; Boccalatte M; Perrone-Filardi P; Cappelli-Bigazzi ; Briguori C; Manganelli F; Ciampi Q; Salvatore M; Chiariello M
Am J Cardiol; 1996 Aug; 78(4):451-7. PubMed ID: 8752192
[TBL] [Abstract][Full Text] [Related]
17. [Hypertrophic cardiomyopathy with restrictive pathophysiology: is there a role for cardiopulmonary exercise testing?].
Correale M; Passero T; Totaro A; Di Biase M
G Ital Cardiol (Rome); 2012 Dec; 13(12):861; author's reply p.861. PubMed ID: 23196690
[No Abstract] [Full Text] [Related]
18. [Apical hypertrophic cardiomyopathy--clinical, electrocardiographic, echocardiographic and hemodynamic evaluation].
Kuśnierz B; Tendera M; Kozielska E; Poloński L; Wantrych M; Wodniecki J
Pol Arch Med Wewn; 1988 May; 79(5):238-47. PubMed ID: 3271303
[No Abstract] [Full Text] [Related]
19. Mavacamten decreases maximal force and Ca
Awinda PO; Watanabe M; Bishaw Y; Huckabee AM; Agonias KB; Kazmierczak K; Szczesna-Cordary D; Tanner BCW
Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H881-H890. PubMed ID: 33337957
[TBL] [Abstract][Full Text] [Related]
20. [Obstructive myocardiopathy and myocardial metabolism. Effect of rapid atrial electrical stimulation alone and coupled with isoproterenol perfusion].
Fernández F; Sprogis W; Belfante M; Bourmayan C; Baclet M; Gerbaux A
Rev Esp Cardiol; 1982; 35(5):423-9. PubMed ID: 6892064
[No Abstract] [Full Text] [Related]
[Next] [New Search]
